A randomized, double blind, placebo-controlled pilot study to assess the efficacy of erenumab in individuals with temporomandibular disorder

Background: Erenumab has proven efficacious in treating migraine headache. Temporomandibular disorder (TMD) is a painful disorder which has high co-occurrence rates with migraine. We hypothesized that erenumab-aooe may also be beneficial in reducing pain in TMD-related myalgia. Methods: This phase II randomized placebo-controlled clinical trial evaluated the safety and efficacy of the off-label use of erenumab in reducing TMD-related pain. The TMD diagnosis was established using the Diagnostic Criteria for Temporomandibular Disorders. The primary outcome was pain interference as assessed by the 0-to-10-point Brief Pain Inventory (BPI). Secondary outcomes were depression, anxiety and somatic symptoms; jaw function; and percent of days taking pain medication. Subjects were randomized at baseline to receive either erenumab 140 mg or placebo administered subcutaneously every 4 weeks for a total of five treatments. Outcome assessments were conducted at baseline, 4, 8, 12, 16, 20 and 24 weeks. Results: Thirty subjects were enrolled with 15 randomized to each treatment group. Baseline pain was mild (BPI interference of 2.19; BPI severity of 2.95). There were no significant treatment effects at any time points with the between-group BPI interference at 24 weeks being −0.19 (95% confidence interval −1.94 to 1.56; p = 0.82). The outcomes were similar between erenumab and placebo for all outcomes except the Patient Health Questionnaire 4-item scale (PHQ-4) which showed that depression/anxiety symptoms were modestly worse (p = 0.03) in the erenumab group. Five participants withdrew during the trial (4 in erenumab arm, 1 in placebo arm). Conclusions: Erenumab was not efficacious in reducing TMD myalgic pain in this phase II trial of 30 subjects with relatively mild pain. Clinical Trial Registration: The study was registered in clinicaltrials.gov (ID: NCT04884763).

Temporomandibular disorder; Erenumab; Clinical trial; Myalgia; Pain

[1] Hargreaves R, Olesen J. Calcitonin gene‐related peptide modulators—the history and renaissance of a new migraine drug class. Headache. 2019; 59: 951–970.

[2] Fernández-Bravo-Rodrigo J, Cavero-Redondo I, Lucerón-Lucas-Torres M, Martínez-García I, Flor-García A, Barreda-Hernández D, et al. Real-world effectiveness and safety of erenumab for the treatment of migraine: a systematic review and meta-analysis. European Journal of Pharmacology. 2024; 976: 176702.

[3] Bomtempo FF, Rocha RB, Cenci GI, Nager GB, Telles JPM. Long-term safety and effectiveness of erenumab in patients with migraine: a systematic review and single-arm meta-analysis. Clinical Drug Investigation. 2023; 43: 45–59.

[4] Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F, et al. Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. European Journal of Neurology. 2021; 28: 1716–1725.

[5] Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia. 2023; 43: 3331024231159366.

[6] Oliveira R, Gil-Gouveia R, Puledda F. CGRP-targeted medication in chronic migraine-systematic review. The Journal of Headache and Pain. 2024; 25: 51.

[7] Dibello V, Lozupone M, Sardone R, Ballini A, Lafornara D, Dibello A, et al. Temporomandibular disorders as contributors to primary headaches: a systematic review. Journal of Oral & Facial Pain and Headache. 2023; 37: 91–100.

[8] Yakkaphan P, Smith JG, Chana P, Renton T, Lambru G. Temporomandibular disorder and headache prevalence: a systematic review and meta-analysis. Cephalalgia Reports. 2022; 5: 25158163221097352.

[9] Durham J, Aggarwal VR, Davies S, Harrison S, Jagger R, Leeson R, et al. Temporomandibular disorders (TMDs): an update and management guidance for primary care from the UK Specialist Interest Group in Orofacial Pain and TMDs (USOT). Royal College of Surgeons of England: London. 2013.

[10] Ryan J, Akhter R, Hassan N, Hilton G, Wickham J, Ibaragi S. Epidemiology of temporomandibular disorder in the general population: a systematic review. Advances in Dentistry & Oral Health. 2019; 10: 555787.

[11] AlSahman L, AlBagieh H, AlSahman R. Oral health-related quality of life in temporomandibular disorder patients and healthy subjects—a systematic review and meta-analysis. Diagnostics. 2024; 14: 2183.

[12] Neves D, Blanco Rueda JA, Caramelo F, Rodrigues MJ, López-Valverde N. Impact of chronic painful temporomandibular disorders on quality of life. Journal of Oral & Facial Pain and Headache. 2024; 38: 9097.

[13] Yost O, Liverman CT, English R, Mackey S, Bond EC. Temporomandibular disorders: priorities for research and care. National Academies of Science Press: Washington, DC. 2020.

[14] Maixner W, Fillingim RB, Williams DA, Smith SB, Slade GD. Overlapping chronic pain conditions: implications for diagnosis and classification. The Journal of Pain. 2016; 17: T93–T107.

[15] Noseda R, Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain. 2013; 154: S44–S53.

[16] Iyengar S, Johnson KW, Ossipov MH, Aurora SK. CGRP and the trigeminal system in migraine. Headache. 2019; 59: 659–681.

[17] De Leeuw R, Klasser GD. Orofacial pain: guidelines for assessment, diagnosis, and management. 6th edn. Quintessence Publishing Company: Batavia. 2018.

[18] Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet JP, et al.; International RDC/TMD Consortium Network, International association for Dental Research; Orofacial Pain Special Interest Group, International Association for the Study of Pain. Diagnostic criteria for temporomandibular disorders (DC/TMD) for clinical and research applications: recommendations of the International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Group†. Journal of Oral & Facial Pain and Headache. 2014; 28: 6–27.

[19] Ohrbach R. Diagnostic criteria for temporomandibular disorders assessment instruments. 2014. Available at: https://www.webcitation.org/6dBvdLXj7 (Accessed: 24 October 2024).

[20] Kroenke K, Krebs EE, Turk D, Von Korff M, Bair MJ, Allen KD, et al. Core outcome measures for chronic musculoskeletal pain research: recommendations from a Veterans health administration work group. Pain Medicine. 2019; 20: 1500–1508.

[21] Reed DE, Stump TE, Monahan PO, Kroenke K. Comparable minimally important differences and responsiveness of brief pain inventory and PEG pain scales across 6 trials. The Journal of Pain. 2024; 25: 142–152.

[22] Selvam K, Kumar JA, Lakshmi SJ, Balasubramanian SK. Brief pain inventory and mcgill pain questionnaire in assessing the patients with temporomandibular joint disorders—a cross-sectional study. Journal of Indian Academy of Oral Medicine and Radiology. 2024; 36: 362–365.

[23] Jumbo SU, MacDermid JC, Kalu ME, Packham TL, Athwal GS, Faber KJ. Measurement properties of the brief pain inventory-short form (BPI-SF) and revised short mcgill pain questionnaire version-2 (SF-MPQ-2) in pain-related musculoskeletal conditions: a systematic review. The Clinical Journal of Pain. 2021; 37: 454–474.

[24] Kroenke K, Evans E, Weitlauf S, McCalley S, Porter B, Williams T, et al. Comprehensive vs. assisted management of mood and pain symptoms (CAMMPS) trial: study design and sample characteristics. Contemporary Clinical Trials. 2018; 64: 179–187.

[25] Kroenke K, Spitzer RL, Williams JBW, Lowe B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics. 2009; 50: 613–621.

[26] Wicke FS, Krakau L, Löwe B, Beutel ME, Brähler E. Update of the standardization of the patient health questionnaire-4 (PHQ-4) in the general population. Journal of Affective Disorders. 2022; 312: 310–314.

[27] Kazlauskas E, Gelezelyte O, Kvedaraite M, Ajdukovic D, Johannesson KB, Böttche M, et al. Psychometric properties of the Patient Health Questionnaire-4 (PHQ-4) in 9230 adults across seven European countries: findings from the ESTSS ADJUST study. Journal of Affective Disorders. 2023; 335: 18–23.

[28] Ohrbach R, Granger C, List T, Dworkin S. Preliminary development and validation of the jaw functional limitation scale. Community Dentistry and Oral Epidemiology. 2008; 36: 228–236.

[29] Yap AU, Lei J, Liu C, Fu KY. Characteristics of painful temporomandibular disorders and their influence on jaw functional limitation and oral health‐related quality of life. Journal of Oral Rehabilitation. 2024; 51: 1748–1758.

[30] Hybelius J, Kosic A, Salomonsson S, Wachtler C, Wallert J, Nordin S, et al. Measurement properties of the patient health questionnaire-15 and somatic symptom scale-8: a systematic review and meta-analysis. JAMA Network Open. 2024; 7: e2446603.

[31] Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharmaceutical Statistics. 2005; 4: 287–291.

[32] Cocks K, Torgerson DJ. Sample size calculations for pilot randomized trials: a confidence interval approach. Journal of Clinical Epidemiology. 2013; 66: 197–201.

[33] Woo A, Lechner B, Fu T, Wong CS, Chiu N, Lam H, et al. Cut points for mild, moderate, and severe pain among cancer and non-cancer patients: a literature review. Annals of Palliative medicine. 2015; 4: 176–183.

[34] Porporatti AL, Costa YM, Réus JC, Stuginski-Barbosa J, Conti PCR, Velly AM, et al. Placebo and nocebo response magnitude on temporomandibular disorder‐related pain: a systematic review and meta‐analysis. Journal of Oral Rehabilitation. 2019; 46: 862–882.

[35] de Vries Lentsch S, van der Arend BW, de Boer I, van Zwet EW, MaassenVanDenBrink A, Terwindt GM. Depression and treatment with anti‐calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine. European Journal of Neurology. 2024; 31: e16106.

[36] Sessa M, Andersen M. New insight on the safety of erenumab: an analysis of spontaneous reports of adverse events recorded in the US Food and Drug administration adverse event reporting system database. BioDrugs. 2021; 35: 215–227.

[37] Tepper SJ, Sheikh HU, Dougherty CO, Nahas SJ, Winner PK, Karanam AK, et al. Erenumab dosage for migraine prevention: an evidence‐based narrative review with recommendations. Headache. 2022; 62: 420–435.

[38] Lattanzi S, Brigo F, Trinka E, Vernieri F, Corradetti T, Dobran M, et al. Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety. Drugs. 2019; 79: 417–431.

[39] Zhu C, Guan J, Xiao H, Luo W, Tong R. Erenumab safety and efficacy in migraine: a systematic review and meta-analysis of randomized clinical trials. Medicine. 2019; 98: e18483.